Redeye initiates coverage of 2cureX, a diagnostics company set to commercialize its precision test for colorectal cancer drugs. IndiTreat’s enabling of targeted individual treatment, with potential positive clinical trial results in Q1 2021, lays the ground for substantial future sales. Although the share has soared lately, the case still offers additional upside in the short to medium term.